Smart drugs: tyrosine kinase inhibitors in cancer therapy.

Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors. While most novel, target-directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated "smart drugs" to fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in their progress through clinical development.

[1]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[4]  D. Slamon,et al.  INTRODUCTION Translational Research: The Role of VEGF in Tumor Angiogenesis , 2000 .

[5]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[6]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[7]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[8]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[9]  D. Slamon,et al.  INTRODUCTION Translational Research: The Role of VEGF in Tumor Angiogenesis , 2000 .

[10]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[11]  C. Barthe,et al.  Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.

[12]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[13]  B. Druker,et al.  Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.

[14]  G. Krystal,et al.  Coexpression of the c-kit and stem cell factor genes in breast carcinomas. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[16]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[17]  D. Slamon,et al.  Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.

[18]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[19]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[20]  M. Debiec‐Rychter,et al.  A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. , 1999, Journal of experimental & clinical cancer research : CR.

[21]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[22]  D. Hallahan,et al.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.

[23]  H. Kitayama,et al.  Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. , 1993, Leukemia & lymphoma.

[24]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[26]  C. Heldin,et al.  Involvement of platelet-derived growth factor in disease: development of specific antagonists. , 2001, Advances in cancer research.

[27]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[28]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[29]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[30]  A. Ullrich,et al.  Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. , 1991, Cancer research.

[31]  A R Padhani,et al.  Challenges for imaging angiogenesis. , 2001, The British journal of radiology.

[32]  H. Varmus,et al.  Biochemical mechanisms of oncogene activity: proteins encoded by oncogenes. Introduction. , 1986, Cancer Surveys.

[33]  S. Richards,et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.

[34]  J. Baselga,et al.  Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. , 2001, Seminars in oncology.

[35]  E. De Clercq,et al.  Angiogenesis: regulators and clinical applications. , 2001, Biochemical pharmacology.

[36]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[37]  D. Birnbaum,et al.  ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor , 2000, Nature Cell Biology.

[38]  S. Fox,et al.  Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. , 2001, The Lancet. Oncology.

[39]  R. Seeger,et al.  Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group , 1994 .

[40]  Austin Brown.  SI UNITS , 1975, The Lancet.

[41]  A. Ullrich,et al.  Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. , 1999, Neoplasia.

[42]  J. Folkman.  Angiogenesis research: from laboratory to clinic. , 1999, Forum.

[43]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[44]  A. Bardelli,et al.  Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. , 2001, Current drug targets.

[45]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[46]  S T Pals,et al.  The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. , 2000, Advances in cancer research.

[47]  L. Ellis,et al.  Overview of angiogenesis: Biologic implications for antiangiogenic therapy. , 2001, Seminars in oncology.

[48]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. George,et al.  Platelet-derived growth factor receptors: a therapeutic target in solid tumors. , 2001, Seminars in oncology.

[50]  D. Yu.  Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. , 2001, Seminars in oncology.

[51]  J. Mendelsohn,et al.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[53]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.